CAAS
SPRO icon

Capital Asset Advisory Services’s Spero Therapeutics SPRO Stock Holding History

Capital Asset Advisory Services’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.4K Hold
32,548
– – ﹤0.01% 298
2025
Q4 		$81.7K Hold
32,548
– – ﹤0.01% 289
2025
Q3 		$61.2K Hold
32,548
– – ﹤0.01% 283
2025
Q2 		$94.4K Buy
+32,548
New +$46.8K ﹤0.01% 269

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Asset Advisory Services's SPRO Position: Q1 2026 in Review

Capital Asset Advisory Services held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 32,548 shares worth $92.4K. The position accounts for ﹤0.01% of the portfolio, ranked #298.

Capital Asset Advisory Services first reported a position in SPRO in Q2 2025 and has held it in 4 quarters since. The position peaked at $94.4K in Q2 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Capital Asset Advisory Services held 32,548 shares of Spero Therapeutics worth $92.4K as of Q1 2026.
  • Capital Asset Advisory Services left its Spero Therapeutics share count unchanged in Q1 2026.
  • Spero Therapeutics made up ﹤0.01% of Capital Asset Advisory Services's portfolio in Q1 2026, its #298 holding.
  • Capital Asset Advisory Services first reported a position in Spero Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Capital Asset Advisory Services's Spero Therapeutics position peaked at $94.4K in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Capital Asset Advisory Services's 13F filing for Q1 2026, filed 24 Apr 2026.